Please assess the completion status of the following clinical trial:

Trial Title: SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with advanced or metastatic colorectal cancer (mCRC) and non-mutated (wild-type) KRAS who are planned to receive treatment with panitumumab monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens and without prior treatment with epidermal growth factor receptor (EGFR) antibody~2. Man or woman 18 years of age or older~3. Signed and dated informed consent before the start of specific protocol procedures~4. ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2~5. Bilirubin ≤ 1.5 x ULN, SGOT/SGPT ≤ 2.5 x ULN, AP ≤ 3 x ULN if no evidence of liver metastases or Bilirubin ≤ 3 x ULN, SGOT/SGPT ≤ 5 x ULN, AP ≤ 5 x ULN if evidence of liver metastases~6. Women of child-bearing potential have to use adequate highly effective methods of contraception . Since doxycyline may reduce efficacy of hormonal contraceptives, women of child-bearing potential have to use double-barrier methods within 4 weeks before first intake of study medication, during study participation and at least 6 weeks after last intake of study medication even if using hormonal contraceptives Women are considered to be of child-bearing potential unless they are ≥ 50 years old and for more than 2 years amenorrheic or unless they are surgically sterile.~Exclusion Criteria:~1. Absence of any of the above-listed inclusion criteria~2. Any serious medical condition or psychiatric illness that would interfere with the patient's ability to sign the informed consent form.~3. Allergic reaction to one of the medications to be used~4. Subject allergic to panitumumab or any components of the panitumumab formulation or treatment regimen~5. Prior treatment with EGFR antibody~6. CYP3A4 enzyme inducers, inhibitors, and substrates (eg, phenytoin, phenobarbital, carbamazepine, ketoconazole, rifampicin, rifabutin, and St. John's Wort) ≤ 2 weeks before randomization (itraconazole should be used with caution)~7. Subjects with hypersensitivity to doxycycline, other tetracyclines, or ingredients of doxycycline capsules~8. Systemic treatment with antibiotics which was completed less than 7 days prior to randomization~9. Pregnant and/or breast-feeding women~10. Active participation in other clinical studies in the previous 4 weeks~11. Serious liver function disorders~12. History of, or evidence of, interstitial pneumonitis or pulmonary fibrosis~13. Person who has been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxycycline 100 mg BID oral use (Type: ACTIVE_COMPARATOR): None
- Placebo 100 mg BID oral use (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues